Alzheimer’s disease is one of the biggest health challenges facing aging populations around the world. The condition gradually damages memory, thinking, and the ability to carry out everyday activities.
It is the most common form of dementia and affects millions of people globally. As people live longer, the number of Alzheimer’s cases continues to rise, creating a growing burden for families, caregivers, and healthcare systems.
For many years, scientists have searched for the root cause of Alzheimer’s disease. Most research has focused on a protein called amyloid-beta. This protein can accumulate in the brain and form sticky clumps known as plaques.
These plaques are often found in the brains of people with Alzheimer’s and have long been considered one of the main drivers of the disease. As a result, many experimental treatments have aimed to remove or reduce amyloid-beta buildup.
However, despite decades of research and billions of dollars invested in developing treatments, scientists still do not fully understand what causes Alzheimer’s disease. Many drugs designed to target amyloid plaques have produced limited benefits, leading researchers to explore other possible explanations.
A new study from Yale-NUS College offers a different perspective on how Alzheimer’s may begin. Instead of focusing mainly on protein plaques, the researchers investigated metabolism, the process that allows cells to produce and use energy.
Their findings suggest that problems with cellular energy production may appear before the well-known amyloid-beta plaques begin to accumulate.
At the center of this theory are mitochondria, tiny structures found inside nearly every cell in the body. Mitochondria are often called the powerhouses of the cell because they generate the energy needed for cells to function properly.
Brain cells require enormous amounts of energy to communicate, process information, and maintain healthy connections. Even small disruptions in energy production could have serious consequences over time.
The researchers discovered signs of metabolic dysfunction long before they observed major amyloid-beta buildup. This finding is important because it suggests that energy problems may not simply be a result of Alzheimer’s disease. Instead, they could be one of the earliest events that help trigger the disease process.
To investigate this idea, the research team used a tiny roundworm called Caenorhabditis elegans. Although these worms are simple organisms, they share many important biological processes with humans.
Scientists frequently use them to study aging and disease because their short lifespan allows researchers to observe changes much more quickly than in humans.
The study produced another surprising result when researchers tested Metformin, a medication widely used to treat type 2 diabetes. Metformin has attracted attention in recent years because some scientists believe it may have benefits beyond blood sugar control, including effects on aging and cellular health.
When the worms received Metformin, their metabolic problems improved significantly. The treatment helped restore healthier energy production within their cells. The worms also showed signs of better overall health and lived longer than untreated worms.
These findings raise an intriguing possibility. If metabolic problems occur at the very beginning of Alzheimer’s disease, then treating those problems early might help slow down or even prevent the disease from developing.
Rather than waiting until memory loss becomes noticeable, future therapies could focus on maintaining healthy cellular energy production during aging.
The research also adds support to a growing scientific view that Alzheimer’s disease may be closely linked to the aging process itself. As people grow older, many cellular systems become less efficient, including the mitochondria. Over time, these changes may make brain cells more vulnerable to damage and disease.
While the findings are promising, it is important to remember that this research was conducted in worms rather than humans. Much more research is needed before scientists can determine whether the same processes occur in people and whether treatments like Metformin could help prevent or treat Alzheimer’s disease in humans.
Even so, the study provides an exciting new direction for Alzheimer’s research. It challenges the long-standing belief that amyloid plaques are the earliest cause of the disease and suggests that problems with cellular energy may play a more important role than previously thought.
The study was led by Jan Gruber and published in the journal eLife. By highlighting the importance of metabolism and mitochondrial health, the research opens the door to new approaches that focus on keeping cells functioning efficiently as people age.
If future studies confirm these findings, protecting the body’s energy-producing systems may become an important strategy for preserving memory, supporting brain health, and reducing the risk of Alzheimer’s disease.
Copyright © 2026 Knowridge Science Report. All rights reserved.
